Literature DB >> 15492237

Id2 drives differentiation and suppresses tumor formation in the intestinal epithelium.

Robert G Russell1, Anna Lasorella, Luis E Dettin, Antonio Iavarone.   

Abstract

Oncogenic signals elevate expression of Id2 in multiple tumor types. When deregulated, Id2 inactivates the tumor suppressor proteins retinoblastoma, p107, and p130. Here, we report a novel and unexpected tumor inhibitory function of Id2 in the intestinal epithelium. First, genetic ablation of Id2 in the mouse prevents differentiation and cell cycle arrest of enterocytes at the time of formation of the crypt-villus unit. Later, these developmental abnormalities evolve toward neoplastic transformation with complete penetrance. Id2-null tumors contain severe dysplastic and metaplastic lesions and express aberrant amounts of beta-catenin. Thus, our data are the first to establish a direct requirement of basic helix-loop-helix inhibitors in driving differentiation and define an unexpected role for the retinoblastoma-binding protein Id2 in preventing tumor formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492237     DOI: 10.1158/0008-5472.CAN-04-2095

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Loss of Id2 potentiates the tumorigenic effect of Rb inactivation in a mouse model of retinoblastoma.

Authors:  Solange Landreville; Duanduan Ma; Jun Wu; J William Harbour
Journal:  Curr Eye Res       Date:  2010-05       Impact factor: 2.424

2.  Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.

Authors:  Christoph Renné; Jose Ignacio Martin-Subero; Maren Eickernjäger; Martin-Leo Hansmann; Ralf Küppers; Reiner Siebert; Andreas Bräuninger
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.

Authors:  M J Gray; N A Dallas; G Van Buren; L Xia; A D Yang; R J Somcio; P Gaur; L S Mangala; P E Vivas-Mejia; F Fan; A M Sanguino; G E Gallick; G Lopez-Berestein; A K Sood; L M Ellis
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

4.  Cooperation between HNF-1alpha, Cdx2, and GATA-4 in initiating an enterocytic differentiation program in a normal human intestinal epithelial progenitor cell line.

Authors:  Yannick D Benoit; Fréderic Paré; Caroline Francoeur; Dominique Jean; Eric Tremblay; François Boudreau; Fabrice Escaffit; Jean-François Beaulieu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-02-04       Impact factor: 4.052

5.  Everything has its time: Id2 clocks embryonic specification of Lgr5+ gut stem cells.

Authors:  Kai Kretzschmar; Hans Clevers
Journal:  EMBO J       Date:  2017-03-15       Impact factor: 11.598

Review 6.  Major signaling pathways in intestinal stem cells.

Authors:  Tim Vanuytsel; Stefania Senger; Alessio Fasano; Terez Shea-Donohue
Journal:  Biochim Biophys Acta       Date:  2012-08-16

7.  Id2 controls specification of Lgr5+ intestinal stem cell progenitors during gut development.

Authors:  Lira Nigmatullina; Maxim Norkin; Margarita M Dzama; Berith Messner; Sergi Sayols; Natalia Soshnikova
Journal:  EMBO J       Date:  2017-01-11       Impact factor: 11.598

8.  Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas.

Authors:  Michael D Onken; Justis P Ehlers; Lori A Worley; Jun Makita; Yoshifumi Yokota; J William Harbour
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

9.  Quantitative mass spectrometry of diabetic kidney tubules identifies GRAP as a novel regulator of TGF-beta signaling.

Authors:  Timothy D Cummins; Michelle T Barati; Susan C Coventry; Sarah A Salyer; Jon B Klein; David W Powell
Journal:  Biochim Biophys Acta       Date:  2009-10-22

10.  MYC is a metastasis gene for non-small-cell lung cancer.

Authors:  Ulf R Rapp; Christian Korn; Fatih Ceteci; Christiaan Karreman; Katharina Luetkenhaus; Valentina Serafin; Emanuele Zanucco; Inês Castro; Tamara Potapenko
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.